What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

Original reporting
Published Nov 10, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$COAGNeutralMed
01

Why it matters

The earnings release adds a new loss figure and fresh Phase 2b data, both of which were not previously public, making the article a primary source of material information.

02

Market read

The article provides the first public disclosure of Hemab's Q3 loss and new trial data, offering traders a fresh data point for pricing the stock.

03

What to watch

Potential regulatory timelines and reimbursement uncertainty for rare‑disease therapies.

Relevance 8/10Novelty 8/10Timing: immediate post‑earnings

Background

Hemab Therapeutics (NASDAQ:COAG) is a clinical‑stage biotech focused on bleeding disorders. The Q3 call included financial results and updates on multiple pipeline candidates.

Company-level read

Ticker impact

$COAGNeutralHigh confidence
Context

Hemab Therapeutics reported Q3 loss widening and disclosed new Phase 2b data for its sutacimig program and upcoming trial updates, providing fresh clinical information for investors.

Expected impact

mixed pressure as market weighs larger loss against encouraging trial results

Evidence & confidence

The earnings loss is material, yet the disclosed trial data are a primary, novel catalyst for a biotech.

Market effects

Positive data may lift other rare‑disease biotech peers.

Limited to US‑listed biotech sector.

Low; impact confined to niche therapeutic area.

Counterpoint

The widening loss could signal deeper cash‑burn, outweighing trial optimism.

Key entities

  • Hemab Therapeutics

    Clinical‑stage biotech developing treatments for rare bleeding disorders.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A

$COAGMedAI 8/10

Hemab Begins Pivotal Study Of Potential Preventive Treatment For Glanzmann Thrombasthenia

Hemab Therapeutics (COAG) initiated a Phase 3 trial (SOLARA) for sutacimig, a potential preventive treatment for Glanzmann thrombasthenia (GT). The study aims to enroll 75 participants, with primary endpoint comparing treated bleed rates during treatment vs. run-in period. Sutacimig has received Fast Track, Orphan Drug, and Breakthrough Therapy designations from the FDA. COAG stock is currently trading at $46.30, down 5.55%.